Enrique Álvarez

465 total citations
13 papers, 401 citations indexed

About

Enrique Álvarez is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Enrique Álvarez has authored 13 papers receiving a total of 401 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 5 papers in Oncology and 4 papers in Organic Chemistry. Recurrent topics in Enrique Álvarez's work include Cancer Mechanisms and Therapy (3 papers), Cancer therapeutics and mechanisms (2 papers) and Click Chemistry and Applications (2 papers). Enrique Álvarez is often cited by papers focused on Cancer Mechanisms and Therapy (3 papers), Cancer therapeutics and mechanisms (2 papers) and Click Chemistry and Applications (2 papers). Enrique Álvarez collaborates with scholars based in United States, Spain and Netherlands. Enrique Álvarez's co-authors include Willem J.P Loves, C.L. van der Wilt, Herbert M. Pinedo, Godefridus J. Peters, Iannis Talianidis, Judith R. Kroep, Cornelis J. van Groeningen, Boudewijn J.M. Braakhuis, Epie Boven and Krishna Menon and has published in prestigious journals such as Blood, Cancer Research and British Journal of Cancer.

In The Last Decade

Enrique Álvarez

13 papers receiving 395 citations

Peers

Countries citing papers authored by Enrique Álvarez

Since Specialization

Citations

This map shows the geographic impact of Enrique Álvarez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Enrique Álvarez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Enrique Álvarez more than expected).

Fields of papers citing papers by Enrique Álvarez

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Enrique Álvarez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Enrique Álvarez. The network helps show where Enrique Álvarez may publish in the future.

Co-authorship network of co-authors of Enrique Álvarez

This figure shows the co-authorship network connecting the top 25 collaborators of Enrique Álvarez. A scholar is included among the top collaborators of Enrique Álvarez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Enrique Álvarez. Enrique Álvarez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	A Novel Class of Bifunctional Immunotherapeutic That Exploits a Universal Antibody Binding Terminus (uABT) to Recruit Endogenous Antibodies to Cell Expressing CD38 Demonstrate In Vivo efficacy in Three Distinct Animal Models 2019 ·Blood ·Anna Bunin, (unknown), Ann Marie Rossi, Matthew Welsch, Christian M. Vidal, (unknown), David A. Spiegel, Luca Rastelli, Enrique Álvarez	3
2	c-Jun N-Terminal Kinase Phosphorylation Is a Biomarker of Plitidepsin Activity 2013 ·Marine Drugs ·María José Muñoz-Alonso, Enrique Álvarez, (unknown), Marina Pollán, Pablo Avilés, Carlos M. Galmarini, Alberto Múñoz	8
3	Abstract A28: A murine model for cancer treatment-related fatigue 2009 ·Molecular Cancer Therapeutics ·Kimberly Pouliot, Enrique Álvarez, Brynmor A. Watkins, Edward G. Fey, Stephen T. Sonis	1
4	Antitumour and antiangiogenic effects of Aplidin® in the 5TMM syngeneic models of multiple myeloma 2008 ·British Journal of Cancer ·Jo Caers, Eline Menu, Hendrik De Raeve, Doreen LePage, Els Van Valckenborgh, Benjamin Van Camp, Enrique Álvarez, Karin Vanderkerken	33
5	JNK activation as an in vivo marker of Aplidin® activity. 2007 ·Cancer Research ·María José Muñoz, Enrique Álvarez, Teresa Martı́nez, Laura González-Santiago, Halina Sasak, Doreen LePage, (unknown), Alberto Múñoz	4
6	Plitidepsin Has a Dual Effect Inhibiting Cell Cycle and Inducing Apoptosis via Rac1/c-Jun NH2-Terminal Kinase Activation in Human Melanoma Cells 2007 ·Journal of Pharmacology and Experimental Therapeutics ·María José Muñoz-Alonso, Laura González-Santiago, Natasha Zarich, Teresa Martı́nez, Enrique Álvarez, José M. Rojas, Alberto Múñoz	44
7	Proteomic Analysis of the Resistance to Aplidin in Human Cancer Cells 2007 ·Journal of Proteome Research ·Laura González-Santiago, Patricia Alfonso, Yajaira Suárez, Antonio Núñez, Luis García‐Fernández, Enrique Álvarez, Alberto Múñoz, J. Ignacio Casal	34
8	Activity of pm02734 against human breast and prostate tumors 2006 ·Cancer Research ·Mariano J. Elices, Doreen LePage, Wendy Grant, Enrique Álvarez, María José Guillén, Carmen Cuevas, (unknown), Glynn Faircloth	3
9	The Role of Deoxycytidine Kinase in Gemcitabine Cytotoxicity 2002 ·Advances in experimental medicine and biology ·C.L. van der Wilt, Judith R. Kroep, Andries M. Bergman, Willem J.P Loves, Enrique Álvarez, Iannis Talianidis, Staffan Eriksson, Cees J. van Groeningen, Herbert M. Pinedo, Godefridus J. Peters	25
10	Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. 2002 ·PubMed ·Judith R. Kroep, Willem J.P Loves, C.L. van der Wilt, Enrique Álvarez, Iannis Talianidis, Epie Boven, Boudewijn J.M. Braakhuis, Cornelis J. van Groeningen, Herbert M. Pinedo, Godefridus J. Peters	161
11	Antitumor activity of cryptophycins: effect of infusion time and combination studies 2000 ·Cancer Chemotherapy and Pharmacology ·Krishna Menon, Enrique Álvarez, (unknown), (unknown), (unknown), Cheng‐Ting Shih, Rima Al‐awar, B A Teicher	24
12	MTA (LY231514) in combination treatment regimens using human tumor xenografts and the EMT-6 murine mammary carcinoma. 1999 ·PubMed ·Beverly A. Teicher, Enrique Álvarez, Liu P, (unknown), Krishna Menon, (unknown), Richard M. Schultz	38
13	Enzymatic rationale and preclinical support for a potent protein kinase Cβ inhibitor in cancer therapy 1999 ·Advances in Enzyme Regulation ·Beverly A. Teicher, Enrique Álvarez, Laurane G. Mendelsohn, Gulshan Ara, Krishna Menon, D. Kirk Ways	23

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact